ClinicalTrials.Veeva

Menu

Intravenous Lidocaine Randomized Comparative Effectiveness Trial

Montefiore Medicine Academic Health System logo

Montefiore Medicine Academic Health System

Status and phase

Completed
Phase 4

Conditions

Abdominal Pain

Treatments

Drug: Hydromorphone
Drug: Lidocaine

Study type

Interventional

Funder types

Other

Identifiers

NCT03300674
2017-8408

Details and patient eligibility

About

This is a randomized, double-blind, emergency department based, comparative effectiveness study of two medication for acute abdominal pain: intravenous lidocaine and intravenous hydromorphone. Patients will be enrolled during an emergency department visit and followed throughout their emergency department course and then by telephone 7 days later.

Enrollment

154 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:Eligible patients are those who present to an ED for treatment of acute abdominal pain. Acute will be defined as pain for no more than seven days. At the time of enrollment, the ED treatment plan must include use of an intravenous opioid.

Exclusion Criteria: Patients will be excluded from participation if they have cardiac conduction system impairment (QTc duration > 0.5s, QRS duration > 0.12s, or PR interval duration > 0.2s), known renal (CKD >2) or liver disease (Childs-Pugh B or greater), are hemodynamically unstable, as determined by the attending physician, are pregnant or breastfeeding, or have a known allergy to either medication. Patients will also be excluded if they have used prescription or illicit opioids within the previous week, or if they have a chronic pain disorder, defined as use of any analgesic medication on more days than not during the month preceding the acute episode of pain. Patients weighing < 60kg or > 120kg will be excluded.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

154 participants in 2 patient groups

Intravenous hydromorphone
Active Comparator group
Description:
Intravenous hydromorphone 1mg. A second dose can be administered at 30 minutes.
Treatment:
Drug: Hydromorphone
Intravenous lidocaine
Active Comparator group
Description:
Intravenous lidocaine 120 mg. A second dose can be administered at 30 minutes
Treatment:
Drug: Lidocaine

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems